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Abstract
Objective—To compare single- and multiple-dose maraviroc exposures in cervicovaginal fluid
(CVF) and vaginal tissue (VT) with blood plasma (BP) and quantify maraviroc protein binding in
CVF.
Design—Open-label pharmacokinetic study.
Methods—In 12 HIV-negative women, 7 paired CVF and BP samples were collected over 12 hours
after 1 maraviroc dose. Subjects then received maraviroc twice daily for 7 days. After the last dose,
subjects underwent CVF and BP sampling as on day 1, with additional sampling during terminal
elimination. VT biopsies were obtained at steady state.
Results—Day 1 and day 7 median maraviroc CVF AUCτ were 1.9- and 2.7-fold higher,
respectively, than BP. On day 1, 6 of 12 subjects had detectable maraviroc CVF concentrations within
1 hour; 12 of 12 were detectable within 2 hours, and all exceeded the protein-free IC90. On day 7,
maraviroc CVF protein binding was 7.6% and the VT AUCτ was 1.9-fold higher than BP. Maraviroc
CVF concentrations 72 hours after dose and BP concentrations 12 hours after dose were similar.
Conclusions—Higher maraviroc exposure in the female genital tract provides a pharmacologic
basis for further evaluation of chemokine receptor 5 antagonists in HIV infection prophylaxis. This
is the first study to report antiretroviral VT concentrations, CVF protein binding, and CVF terminal
elimination.
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HIV/AIDS continues to be a serious public health concern that demands attention. Although
antiretroviral therapy has drastically reduced HIV-associated mortality and improved the
quality of life of those living with HIV infection,1–3 for every person treated, 4 new people
become infected.1 Sexual transmission of HIV remains the primary mode of HIV transmission
worldwide.1,4 Without an effective vaccine, alternative strategies to prevent the sexual
transmission of HIV are critical.
There are 3 ways antiretroviral therapy can be used to prevent HIV transmission: pre-exposure
prophylaxis (PrEP) (both topically and orally), postexposure prophylaxis (PEP) (orally), and
treatment of the infected individual to reduce HIV replication in genital secretions. As females
are especially vulnerable to the sexual transmission of HIV, understanding the degree to which
antiretrovirals (ARVs) concentrate in the female genital tract is particularly important in both
primary and secondary prevention.4–7
Discordance in exposure of ARVs between the genital tract and blood plasma (BP) has both
individual and public health implications. On an individual level, there is a risk for harboring
resistant virus in sanctuary sites such as the genital tract, which in turn can potentially reseed
the systemic compartment resulting in treatment failure. From a public health perspective,
inadequate penetration of ARVs into the female genital tract may result in ongoing genital
shedding, even in the presence of suppressed plasma HIV RNA, thereby increasing the risk of
sexual transmission of HIV.8–10
Although the exact mechanism of the sexual transmission of HIV-1 within the female genital
tract is not fully understood, viruses that utilize the CCR5 chemokine receptor predominate in
the early stages of mucosal transmission.5,6,11–14 Modeling of a male-to-female transmission
has proposed a direct correlation between the number of endocervical CCR5 receptors and the
probability of HIV-1 infection.14 Therefore, the CCR5 receptor is an appealing target for HIV
prophylaxis. Proof of concept has been demonstrated in a nonhuman primate model using a
novel oral CCR5 receptor antagonist (CMPD167). After vaginal simian HIV (SHIV) challenge,
CMPD167 could both prevent infection and lower the viral set point after infection.15
The present study was designed to understand CCR5 antagonist exposure in the human female
genital tract. Using the commercially available CCR5 antagonist maraviroc (Celsentri/
Selzentry; Pfizer, Inc, New York, NY), single- and multiple-dose exposures in cervicovaginal
fluid (CVF), BP, and vaginal tissue (VT) were investigated.
METHODS
Study Design and Subject Selection
This 10-day, open-label, pharmacokinetic (PK) study in healthy HIV-negative female
volunteers was conducted between April 2007 and June 2007 at the University of North
Carolina at Chapel Hill (UNC). All subjects provided written informed consent, including a
separate consent for HIV testing. The protocol was approved by the UNC Biomedical
Institutional Review Board.
Subjects were eligible to participate if they were healthy premenopausal females with an intact
uterus and cervix and body mass index between 18 and 30 kg/m2 with a total body weight ≥50
kg. Subjects were required to be between the ages of 18 and 49 years and using an acceptable
form of birth control. Subjects were excluded if they were pregnant or nursing, had a history
of regular alcohol consumption, or currently smoking more than 5 cigarettes per day. Subjects
with a history of loop electrosurgical excision procedure, conization, or cryosurgery were
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excluded to minimize any potential variability in sample collection. Subjects were excluded
for a positive urine drug screen; presence of a sexually transmitted infection; or infection with
HIV-1, hepatitis B, or hepatitis C. Subjects were excluded for any abnormal screening
laboratory results or any clinically significant abnormality on physical and/or pelvic
examination deemed by the study safety officer to increase subject risk or compromise study
results. Subjects were excluded from study participation if they exhibited signs and symptoms
of orthostasis or a QTc >450 milliseconds. Twelve-lead electrocardiogram (EKG) testing was
performed per standard Pfizer protocol for healthy volunteer studies. Subjects were permitted
to use oral hormonal contraceptives and up to 1 g/d of acetaminophen. All other medications
were discontinued at least 7 days before study drug dosing and could not be restarted until after
study completion. Subjects were instructed to abstain from sexual intercourse and the use of
vaginal products from 48 hours before dosing until study discharge.
Screening procedures occurred within the 28 days before maraviroc dosing. Comprehensive
laboratory studies, including a complete blood count with differential, liver function tests,
serum chemistries, hepatitis B and C serology panels, urinalysis, and serum pregnancy testing,
and sexually transmitted infection evaluations, were performed at the screening visit. Sexually
transmitted infection evaluations included testing for gonorrhea, chlamydia, trichomoniasis
(Aptima Combo 2 and Aptima TV ASR Kits; Gen-Probe Incorporated, San Diego, CA),
bacterial vaginosis (QuickVue Advance pH and amine kit; Quidel Corp, San Diego, CA), and
syphilis. Hepatitis simplex virus-2 antibody (Focus Diagnostics, Cypress, CA) was measured
if indicated by the presence of suspected herpetic lesions on examination. All subjects
underwent anonymous HIV testing using a standard HIV-1/2 enzyme-linked immunosorbent
assay with pooled HIV-1 polymerase chain reaction testing.16 All testing was performed in the
McLendon Laboratories of UNC Hospitals or in the UNC Sexually Transmitted Diseases
Cooperative Research Center Microbiology Core Lab.
Safety laboratory monitoring was performed on days 0, 4, 8, and follow-up. A full physical
examination was performed at screening and at follow-up, and brief physical examinations
were performed on days 0 and 8. Single supine and standing blood pressure and pulse
measurements and a single 12-lead EKG were obtained on day 0, day 8, and at follow-up.
Study Visits
During the treatment phase of the study, subjects received maraviroc 300 mg orally twice daily
on days 1–6 and a single 300-mg dose in the morning of day 7. To obtain maximal CVF volume,
day 1 was scheduled to occur within 7–10 days after the end of the subject's menses. Subjects
were admitted the evening before day 1 to the UNC Verne S. Caviness General Clinical
Research Center (CRC) for intensive PK sampling. Subjects fasted for 8 hours before dosing
and 4 hours after dosing on days 1 and 7 and refrained from drinking water for at least 1 hour
before and after the maraviroc dose. In the morning of day 1, paired BP and CVF samples were
obtained at pre-dose, 1, 2, 4, 6, 8, and 12 hours after first dose. Standard meals were provided
to subjects at the appropriate times. Subjects returned to the CRC each morning on days 2–6
for trough BP and CVF PK sampling before the morning dose of study medication. Subjects
were instructed to fast for 2 hours before and 1 hour after the morning dose and to restrict water
intake for 1 hour before and after dose. Morning doses were witnessed, and subjects were given
the evening dose to take home with a diary to record the time of dosing. Subjects were directed
to follow the same dosing instructions in the evening. Subjects were readmitted to the CRC in
the evening of day 6. In the morning of day 7, intensive BP and CVF PK sampling identical
to day 1 was performed. A single VT biopsy was obtained at one of the following time points
after dose: 2, 4, 8, and 12 hours. Subjects remained in the CRC until the morning of day 8. At
this time, a 24-hour post-dose BP and CVF PK sample was obtained and safety studies were
conducted. All subjects returned to the CRC in the mornings of days 9 and 10 for BP and CVF
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PK sampling 48 and 72 hours after the final dose. Subjects returned for a safety follow-up visit
7–10 days after the last dose of maraviroc.
Sample Collection and Processing
CVF samples were self-collected via direct aspiration with a volumetric aspiration device.17,
18 After collection, CVF was transferred to labeled cryovials and stored at −80°C until analysis.
Whole blood was obtained using sodium heparin–containing collection tubes (BD Diagnostics,
Franklin Lakes, NJ) and centrifuged at 1300g at 4°C for 10 minutes. The resulting BP was
aliquoted into labeled cryovials and stored at −80°C until analysis.
VT was collected by biopsy. Briefly, subjects were placed in the dorsal lithotomy position, and
CVF was collected with the aspirator by the clinician before speculum insertion. After
speculum insertion, the right or left vaginal fornix was cleaned with povidone–iodine, the
anticipated biopsy site was anesthetized with topical 20% benzocaine spray (HurriCaine;
Beutlich Pharmaceuticals, Waukegan, IL), and an approximately 3 × 3 × 1-mm specimen was
obtained using Baby Tischler forceps (Cooper Surgical, Trumbull, CT). Samples were placed
in a labeled screw-capped polypropylene tube, immediately snap frozen in liquid nitrogen, and
stored at −80°C until analysis.
Protein precipitation was used to prepare BP, CVF, and tissue samples for analysis. Briefly,
to 50 μL of BP, CVF, or VT homogenate, 700 μL of an acetonitrile solution containing 1 mg/
mL of the internal standard maraviroc-d5 was added. After vortex and centrifugation, 400 μL
of supernatant was transferred to a clean tube and tightly sealed for analysis.
After maraviroc concentration analysis, remaining day 7 samples of CVF were pooled for
equilibrium dialysis to determine protein binding. Pooling of samples was necessary due to
the volume (many samples < 500 μL) of CVF collected at each time point. Briefly, 200 μL of
pooled CVF sample was incubated at 37°C for 16 hours in rapid equilibrium dialysis cartridges
(Pierce Biotechnology, Inc, Rockford, IL). Subsequently, 50 μL from the rapid equilibrium
dialysis well was transferred to 1 well of a 96-well plate, and 50 μL of phosphate-buffered
saline added. Similarly, 50 μL from the phosphate-buffered saline well was transferred to 1
well of a 96-well plate, and 50 μL of “blank” vaginal fluid added. These samples were treated
by the protein precipitation method described above before analysis.
Maraviroc concentrations for all samples were analyzed using validated high-performance
liquid chromatography–tandem mass spectrometry methods. All analyses were performed
using a LEAP autosampler (LEAP Technologies, Chapel Hill, NC), a Rheos 2000 liquid
chromatograph (Flux Instruments AG, Basel, Switzerland), a Fluophase PFP column (4.6 ×
50 mm, 5 μm; Thermo Electron Corporation, Pittsburgh, PA), and an API 4000 (MDS Sciex,
Thornhill, Ontario). The API 4000 instrument was used in positive TurboIonSpray mode, with
a source temperature of 550°C. The mobile phase consisted of 80:20 vol:vol acetonitrile:25
mM ammonium acetate in aqueous 0.2% formic acid, at a flow rate of 1 μL/min. Analytes were
detected using multiple reaction monitoring, and the precursor/product ion transitions were m/
z 514.1→389.1 for maraviroc and m/z 519.1→394.1 for maraviroc-d5. The dynamic range of
the assay was 0.5–500 ng/mL for BP and CVF and 20–20,000 ng/g for VT.
Validations for BP, CVF, VT, and protein binding demonstrated maraviroc recoveries of ≥80%
for all matrices. Accuracy and imprecision experiments demonstrated that for the lower limit
of quantification (LLQ), the overall mean concentration deviated ≤20.0% from target, with
relative standard deviation (RSD) ≤20.0%. For the low, medium, and high controls, overall
mean concentration deviated ≤15.0% from target, with an RSD ≤15.0%
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Subject demographic information was collected and summarized descriptively. BP and CVF
PK parameters were estimated using noncompartmental methods. The maximum concentration
(Cmax) was estimated directly from experimental data; Tmax was defined as the time of first
occurrence of Cmax. The area under the plasma concentration–time curve (AUC) within the
dosing interval (τ), where τ = 12 hours for maraviroc, was estimated using the log-linear
trapezoidal method. To compare exposure in the genital tract with that of BP, CVF:BP
AUCτ ratios were calculated for days 1 and 7. To describe multidose accumulation in BP and
CVF, day 7:day 1 AUCτ ratios were calculated. BP and CVF C12h (Cmin) concentrations
collected on days 2–6 were plotted per subject and visually inspected to confirm steady state
conditions on day 7.
To perform a concentration comparison between VT and CVF and BP, an estimated tissue
density of 1.05 g/mL was used to convert nanograms per gram to nanograms per milli-liter.
To estimate VT PK parameters, a composite approach was used: At each time point, the median
VT concentration was calculated and the composite concentration–time profile generated. To
compare median exposure in VT samples relative to BP, this composite AUCτ was divided by
the median BP AUCτ on day 7 to provide a VT:BP AUC ratio.
Descriptive statistics were generated by SAS Institute, Inc (Cary, NC), software version 8.2.
Data are presented as median (interquartile range), unless otherwise specified.
RESULTS
Subject Demographics, Disposition, and Safety
Of 21 women screened for this study, 13 were enrolled in the protocol and 12 provided PK
samples. One subject was withdrawn by investigators due to active vaginal bleeding at the first
study visit, related to a missed oral contraceptive tablet earlier in the week of the scheduled
visit; maraviroc was not administered, and this subject did not contribute any data.
Demographic information is presented in Table 1. The mean age of the 12 participants was
26.9 years, mean weight was 63.0 kg, and the mean body mass index was 22.2 kg/m2. Six of
12 subjects were white. Nine of 12 women received concomitant oral contraceptive therapy.
Of these 12 subjects, 1 withdrew from the protocol for personal reasons before the day 7 PK
visit. An additional subject did not complete maraviroc blood sampling or vaginal biopsy on
day 7 but did complete day 7 CVF collections due to a vasovagal response at the 4 hours post-
dose blood draw. The study physician/safety officer deemed this vasovagal reaction to be
unrelated to study medication, as this event occurred in relation to obtaining a BP sample; the
subject was supine at the time of the episode, and the subject reported similar reactions during
phlebotomy in the past. She recovered fully before discharge on day 8. The remaining 10
subjects completed the protocol as planned.
Subjects tolerated the study medication well. The majority of adverse events (AEs) were mild
in severity, and there were no serious AEs reported. The most frequently reported AEs were
fatigue (25%), nausea (17%), and headache (17%), similar to previous reports. Eosinophilia,
tinnitus, vomiting, abdominal pain, flatulence, and somnolence were reported by at least 1
subject and attributed to maraviroc. No EKG abnormalities were related to maraviroc
administration. Subjects also tolerated CVF and VT sampling well; post-biopsy vaginal
bleeding was minimal and resolved within 24–48 hours of the procedure.
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BP and CVF Pharmacokinetics
Figures 1A and B depict the median (interquartile range) BP and CVF concentrations for all
subjects at day 1 (n = 12) and day 7 (n = 10), respectively. One hour after the first dose of
maraviroc (the earliest sampling time point), BP concentrations were detectable in 12 of 12
women and CVF concentrations were detectable in 6 of 12 women. By 2 hours, 12 of 12 women
had detectable maraviroc in their CVF. Median CVF concentrations surpassed BP
concentrations by 4 hours and remained higher than BP for the duration of the dosing interval.
On day 7, median CVF concentrations were consistently higher than BP after the 4-hour time
point.
Figure 1C shows BP and CVF trough concentrations (Cmin) obtained immediately before
dosing on days 2–6. Blood draws on days 2–6 were occasionally omitted due to concerns over
multiple needle insertions, limiting the ability to obtain venous access for PK sampling on day
7. This is reflected in 11 BP samples obtained on day 3 and in only 6 BP samples obtained on
day 5. However, all subjects provided all scheduled CVF samples. All samples collected had
detectable maraviroc concentrations, and CVF trough concentrations were consistently higher
than those of BP. These data also confirmed that steady state conditions were achieved by day
7.
Table 2 summarizes the PK parameters for each matrix, along with accumulation ratios (day
7:day 1) and CVF:BP ratios. Maraviroc BP parameters were consistent with data from historical
controls.19,20 Time to maximal concentration (Tmax) at day 7 was delayed 3 hours in CVF
compared with BP, and maximal concentrations (Cmax) in CVF at day 7 were 2.2-fold higher
than in BP. Maraviroc moderately accumulated in BP over 7 days of dosing by 26% [day 7:day
1 AUCτ ratio = 1.26 (1.16–1.30)]. However, maraviroc significantly accumulated in CVF by
213% [day 7:day 1 AUCτ ratio = 2.13 (1.16–2.59)]. When CVF exposure was compared with
BP exposure, the CVF:BP AUCτ ratio on day 1 was 1.91 (0.82–4.77) and on day 7 was 2.73
(1.0–5.39). This demonstrates that CVF exposures were approximately 2-fold higher than BP
on day 1 and 2.7-fold higher than BP on day 7. Individual CVF:BP AUC ratios for days 1 and
7 are shown in Figure 1D. No correlation was found between BP exposure and CVF exposure
either on day 1 or on day 7 of dosing.
Single VT samples were collected from 10 subjects; 3 subjects’ samples were collected at each
of the 2- and 4-hour post-dose time points, and 2 subjects’ samples were collected at each of
the 8- and 12-hour post-dose time points. Tissue concentrations were measured in nanograms
per gram and corrected for tissue density (1.05 g/mL) to determine an equivalent concentration
in nanograms per milliliter. The median VT concentrations are shown in Figure 2A, along with
the comparative BP and CVF median concentrations over the dosing interval on day 7. VT
composite PK parameter estimates are provided in Table 2. Maraviroc VT exposure was 1.9-
fold higher than BP exposure and approximately 65% of the CVF exposure (VT:CVF AUCτ
ratio = 0.65).
After 7 days of dosing, the terminal elimination of maraviroc in BP and CVF was evaluated
by sampling 24, 48, and 72 hours after the final dose (Fig. 2B). CVF concentrations exhibited
a linear and predictable decline and paralleled that of BP. CVF concentrations were
approximately 10 times higher than BP at the end of the 12-hour dosing interval, and CVF
concentrations at 72 hours after dose were similar to BP concentrations 12 hours after dosing.
Protein binding was performed on pooled CVF samples obtained during day 7 of maraviroc
dosing. Ten samples at, or close to, Cmax were pooled into 4 samples for analyses. In these
samples, protein binding ranged from 3.7% to 13.6% with a mean of 7.6%.
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This study investigated the female genital tract exposure of maraviroc, the first commercially
available CCR5 antagonist. This comprehensive evaluation also included, for the first time,
measurements of VT concentrations, CVF protein binding, and terminal elimination of drug
in cervicovaginal secretions. Maraviroc achieved one of the highest CVF exposures of 17
ARVs evaluated to date.17,18,21,22 Based on the physicochemical properties of maraviroc, in
addition to its protein binding affinity, these results were unexpected. CVF exposures exceeded
those of plasma by a median of 1.9-fold and 2.7-fold after single and multiple dosing,
respectively. Additionally, maraviroc CVF concentrations were observed in 50% of the women
1 hour after dosing and in 100% of the women 2 hours after dosing. VT exposures were 1.9-
fold higher than plasma at steady state. All concentrations were well above the protein-free
IC90 of 0.5 ng/mL.23
The mechanism for these increased GT concentrations is not known but could be related to
drug transport or altered drug metabolism in genital tract tissue. Little is known about the drug
disposition properties of the female GT, although P-glycoprotein (an efflux transporter) has
been found in several female GT tissues.24 Additionally, compared with systemic drug
exposure, disproportionately increased seminal concentrations of the protease inhibitor
indinavir in the presence of ritonavir (a potent inhibitor of P-glycoprotein) have been described,
25 providing support for the potential role of drug transporters in GT drug disposition. However,
no such data exist in women. Elucidating the determinants of drug penetration in the GT has
important implications for PrEP/PEP, if drug properties or physiologic mechanisms can be
manipulated to improve ARV exposure.
Although this study did not measure maraviroc's affinity for CCR5 receptors on cervical
mononuclear cells, receptor occupancy has not been shown to correlate with efficacy in HIV-
infected subjects.26 However, protein-free concentrations ≥0.5 ng/mL have been demonstrated
effective against a wide variety of HIV isolates in cultured donor peripheral blood mononuclear
cells.23 Median protein-free maraviroc CVF concentrations were 10-fold higher than this value
1 hour after a single dose and were >800-fold higher than this value at Cmin under steady state
conditions. Therefore, virologic efficacy in this compartment is expected.
Protein binding in the female genital tract was determined for the first time in this study.
Maraviroc protein binding in CVF was approximately 10-fold lower than BP, suggesting that
the majority of drug present in the genital tract is unbound and available for pharmacological
activity. By achieving higher concentrations in the CVF, maraviroc and other ARVs may be
beneficial to HIV-infected women by preventing continued genital tract shedding of HIV,
thereby decreasing the risk of secondary transmission to sexual partners.27–29 Also, a decrease
in genital tract HIV RNA may prevent the emergence of resistant virus within sanctuary sites
such as the genital tract, which may reseed the systemic compartment resulting in treatment
failure. Although evidence suggests that maraviroc plasma concentrations in HIV-infected
patients and healthy volunteers are similar,19 further studies investigating genital tract exposure
and treatment responses of CCR5 inhibitors within the genital tract in HIV-infected women
are warranted.
This study is the first to measure total VT concentrations of an ARV. These data are critical to
understanding the pharmacology of maraviroc in the female genital tract, as it is the tissue,
rather than the CVF, that is the site of HIV infection. It would seem likely that drugs achieving
high exposures in CVF would have correspondingly high concentrations in VT and, likewise,
those achieving low CVF exposures with corresponding low VT concentrations. However,
without a complete understanding of drug transport and metabolism in the female genital tract,
it is premature to extrapolate these results to other ARVs. Although protein-free maraviroc
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tissue concentrations were not determined in this investigation, and biopsy logistics precluded
constructing full tissue PK curves for individual subjects, these data are an important first step
in understanding ARV drug disposition in female genital tract tissues. Understanding protein
binding in female GT tissues will be an important future goal for drugs used in PrEP/PEP.
CCR5 inhibitors may be particularly useful in preventing HIV transmission because viruses
that utilize CCR5 predominate in the early stages of mucosal transmission.5–7,12–15
Additionally, women with genital ulcer disease demonstrate increased CCR5 receptor
concentrations30 and are at an increased risk of contracting HIV via heterosexual contact. Thus,
the use of a CCR5 inhibitor in this high-risk group of patients may be particularly beneficial.
30–32 Maraviroc quickly achieved concentrations above the protein-free IC90 within 2 hours
of administration, suggesting a role in PEP. As maraviroc remained at high concentrations in
the genital tract longer than BP after dosing was suspended, this property may allow for more
convenient episodic dosing in the prevention arena. The female genital tract exposures of other
CCR5 inhibitors in development are currently unknown.
Although pharmacological prophylaxis may be an effective tool in the prevention of
heterosexual HIV transmission, its use must balance the risks and benefits for each patient.
Recent literature has shown promise regarding the limitations associated with both PrEP and
PEP including patient compliance,33–35 cost,36 the development of ARV resistance,37,38 and
toxicities39,40; however, these limitations still exist and must be considered in choosing a PrEP/
PEP regimen. Furthermore, these limitations stress the importance of continued adequate
patient counseling, education, and the consistent use of safe sex practices.
Following these promising pharmacologic results, several important areas of investigation
remain. These include quantifying the effects of maraviroc on genital tract HIV RNA and
sexual infectivity in HIV-infected patients; determining the potential for CCR5 inhibition in
the genital tract to select for transmission of dual–mixed tropic or X4-tropic virus; and the
impact of chronic CCR5 inhibition in areas with endemic tick-borne illnesses41 and West Nile
virus.42 Nonetheless, with a novel mechanism of action, excellent oral bioavailability, and high
genital tract exposure, maraviroc is an attractive candidate for further investigation in the
prevention of heterosexual HIV transmission.
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A, Day 1 (single dose) concentration–time profile of maraviroc in BP and CVF for 12 subjects
over the 12-hour dosing interval [data presented as median (IQR)]. B, Day 7 (multiple dose)
concentration–time profile of maraviroc in BP and CVF for 10 subjects over the 12-hour dosing
interval [data presented as median (IQR)]. C, Trough (Cmin) concentration of maraviroc in BP
and CVF over days 2–6 of dosing [data presented as median (IQR)]. For all CVF time points,
n = 12; for BP, day 3 included 11 subjects and day 5 included 6 subjects. D, Individual CVF:BP
AUC ratios calculated over a day 1 and day 7 dosing interval. IQR, interquartile range.
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A, VT concentrations of maraviroc in relation to BP and CVF concentrations, within a dosing
interval on day 7 (multiple dose) [data presented as median (IQR)]. An estimated tissue density
of 1.05 g/mL was used to convert VT concentration from nanograms per gram to nanograms
per milliliter. B, Day 7 (multiple dose) concentration–time profile of maraviroc in BP and CVF
over 72 hours post-dose for 10 subjects [data presented as median (IQR)]. IQR, interquartile
range.
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TABLE 1
Demographics of Study Participants;Data Presented as Mean ± SD or Number (%)
Parameter Result
Age (yrs) 26.9 ± 5.4
Race
    African American 4 (33.3)
    Asian 1 (8.3)
    White 6 (50.0)
    Mixed race 1 (8.3)
Weight (kg) 63.0 ± 6.8
BMI (kg/m2) 22.2 ± 1.9
Oral contraceptives used during study 9 (75)
BMI, body mass index.
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